SOD1 and amyotrophic lateral sclerosis: Other trials targeting specific familial causes of ALS include a promising GAPmer antisense oligonucleotide (ASO) for SOD1 mutation carrying patients (approximately 2% of all ALS cases) recently being approved by the FDA77.